EUVIMEDEUVIMED entdecken
Crossref

Assessment of post-COVID-19 vaccination neutralizing antibodies in kidney transplant and hemodialysis patients versus the general population

Iman I. Sarhan, Mostafa A.N. Abdelgawad, Ahmed A. Emara, Moaaz A.A. Elkader, Ahmed F. Mohamed

Journal of The Egyptian Society of Nephrology and Transplantation · 2024

DOI: 10.4103/esnt.esnt_12_24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of The Egyptian Society of Nephrology and Transplantation, 2024. Verfasst von Iman I. Sarhan und 4 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients receiving hemodialysis (HD) and kidney transplant recipients are immunocompromised populations prioritized for coronavirus disease 2019 (COVID-19) vaccination, however, there were few clinical trials with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine responses. Compared with controls, individuals with chronic kidney disease and those on immunosuppressants have lower antibody titers and rates of seroconversion after vaccination. There is a lack of data on their humoral response to COVID-19 immunization. To study the effect of different types of available COVID-19 vaccines in Egypt (AstraZeneca, Sinopharm, Pfizer/BioNTech, and Sputnik) on neutralizing antibodies against COVID-19 in HD and kidney transplantation patients compared with the healthy population. Patients and methods A total of 84 participants; 28 HD patients, 28 kidney transplant recipients, and 28 healthy medical staff members were recruited to test the serological reaction. Six months following the second dose of the COVID-19 vaccine, we evaluated antibody titers against SARS-CoV-2 by Elecsys Anti-SARS-CoV-2 S (Roch) and collected data from the patients, including their comorbidities and the length of time since their kidney transplant.

Results

All the study groups were comparable as regards age, sex, and BMI, however, hemoglobin was significantly higher in the control group. Antibody response to vaccination was strongest in the control group (100%), followed by HD patients (85%), with transplant recipients showing a significantly weaker response (60%). The Pfizer vaccine generated higher neutralizing antibody levels compared with other vaccines in this study. Yet, the difference was not statistically significant. Additionally, no significant difference in response between the different vaccine types. the transplant group displayed significantly lower levels compared with the control group ( P

Zitieren

APA

Sarhan, I. I., Abdelgawad, M. A., Emara, A. A., Elkader, M. A., & Mohamed, A. F. (2024). Assessment of post-COVID-19 vaccination neutralizing antibodies in kidney transplant and hemodialysis patients versus the general population. Journal of The Egyptian Society of Nephrology and Transplantation. https://doi.org/10.4103/esnt.esnt_12_24

Vancouver

Sarhan II, Abdelgawad MA, Emara AA, Elkader MA, Mohamed AF. Assessment of post-COVID-19 vaccination neutralizing antibodies in kidney transplant and hemodialysis patients versus the general population. Journal of The Egyptian Society of Nephrology and Transplantation. 2024. doi:10.4103/esnt.esnt_12_24

BibTeX
@article{Sarhan2024,
  author = {Sarhan, Iman I. and Abdelgawad, Mostafa A.N. and Emara, Ahmed A. and Elkader, Moaaz A.A. and Mohamed, Ahmed F.},
  title = {Assessment of post-COVID-19 vaccination neutralizing antibodies in kidney transplant and hemodialysis patients versus the general population},
  journal = {Journal of The Egyptian Society of Nephrology and Transplantation},
  year = {2024},
  doi = {10.4103/esnt.esnt_12_24}
}
Kostenlos starten →